Seven Fleet Capital Management LP Makes New $541.72 Million Investment in Evolus, Inc. $EOLS

Seven Fleet Capital Management LP purchased a new stake in shares of Evolus, Inc. (NASDAQ:EOLS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 78,057 shares of the company’s stock, valued at approximately $541,716,000. Seven Fleet Capital Management LP owned 0.12% of Evolus as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Assenagon Asset Management S.A. lifted its holdings in Evolus by 51.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 908,180 shares of the company’s stock valued at $6,303,000 after acquiring an additional 310,035 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of Evolus in the 1st quarter worth approximately $5,289,000. Rice Hall James & Associates LLC bought a new stake in Evolus during the second quarter worth approximately $8,952,000. Deutsche Bank AG bought a new position in shares of Evolus in the second quarter valued at $3,157,000. Finally, Pinnacle Associates Ltd. lifted its position in shares of Evolus by 15.9% during the 4th quarter. Pinnacle Associates Ltd. now owns 782,365 shares of the company’s stock valued at $5,203,000 after acquiring an additional 107,490 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Stock Performance

Shares of NASDAQ EOLS opened at $8.78 on Thursday. The business has a 50 day simple moving average of $6.95 and a 200 day simple moving average of $5.86. Evolus, Inc. has a 52 week low of $3.86 and a 52 week high of $9.12. The stock has a market cap of $579.92 million, a price-to-earnings ratio of -16.88 and a beta of 1.35.

Analyst Ratings Changes

EOLS has been the topic of several recent analyst reports. BTIG Research reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, June 17th. Wall Street Zen upgraded Evolus from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings raised Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Evolus in a research report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.